Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hair loss gene clue found?

NCT ID NCT07455708

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a specific gene (NR3C1) that helps control inflammation is linked to alopecia areata, an autoimmune condition that causes hair loss. Researchers compared 120 people with and without the condition to see if gene variations affect disease risk or severity. The goal was to better understand the biology behind the disease, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include 60 patients clinically diagnosed with alopecia areata and 60 age- and sex-matched healthy controls recruited from the same geographic area.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Cases): * Clinically diagnosed alopecia areata * Age ≥ 18 years * Both sexes * Willingness to participate and provide informed consent Inclusion Criteria (Controls): * Apparently healthy individuals * No history of autoimmune disease * Age- and sex-matched to cases * Provided informed consent Exclusion Criteria: * Presence of other autoimmune or inflammatory diseases * Current systemic immunosuppressive therapy * Pregnancy or lactation * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata(AA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Benha University

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.